<DOC>
	<DOCNO>NCT02078661</DOCNO>
	<brief_summary>To evaluate safety efficacy 0.25 % PG101 1.0 % PG101 topical gel suspension compare placebo administer two time daily 14 day subject diagnose dry eye syndrome</brief_summary>
	<brief_title>Safety Efficacy PG101 Dry Eye Syndrome</brief_title>
	<detailed_description>The topical product PG101 expect efficacious treat symptom dry eye discomfort , dryness , grittiness , burning , sting , photophobia , lid friction , mucus discharge hyper-tearing . Two concentration ( 0.25 % 1.0 % ) include study determine dose response effect .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Be male female race , least 18 year age Have provide verbal write informed consent Be able willing follow instruction , include participation study assessment visit Have report history dry eye syndrome Have history use desire use eye drop dry eye If woman childbearing potential , negative pregnancy test Visit 1 use adequate method birth control throughout study period Have best correct visual acuity +0.70 logMAR good eye Have clinically significant eye finding require therapeutic treatment may interfere study parameter Be diagnose ongoing ocular infection ( bacterial , viral , fungal ) , active ocular inflammation ( e.g . follicular conjunctivitis ) Visit 1 Be woman pregnant , nurse plan pregnancy Have know allergy and/or sensitivity test article component Have condition situation investigator feel may put subject significant risk , may confound study result , may interfere significantly subject 's participation study Be currently enrol investigational drug device study use investigational drug device within 30 day Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Keratoconjunctivitis sicca</keyword>
	<keyword>Dry eye</keyword>
</DOC>